Development of anti-HBV agents targeting HBV capsid proteins

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2023 English Publisher:Royal Society of Chemistry (RSC)Journal:RSC Medicinal Chemistry, volume 14, pages 1,973-1,980 (eissn: 2632-8682,

Copyright policy )

Authors: Takuya Kobayakawa; Masayuki Amano; Miyuki Nakayama; Kohei Tsuji; Takahiro Ishii; Yutaro Miura; Kouki Shinohara; +3 Authors

doi: 10.1039/d3md00258f

pmid: 37859721

pmc: PMC10583812

Development of anti-HBV agents targeting HBV capsid proteins

- Summary
- Metrics

Abstract

>Design and synthesis of anti-hepatitis B virus (HBV) agents: A small anti-HBV compound, Cpd4 (1), was identified by in silico screening. Its structure–activity relationship studies discovered a more potent derivative, TKB-HBV-CA-001 (3b).

Related Organizations

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average